An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Part of paid clinical trials in Dallas, Texas.

Sponsor
Derm Texas, PLLC
Study ID
NCT07105254
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
2 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Key Dates

Start date
Aug 1, 2025
Status verified
Aug 2025
Primary completion
May 15, 2026
Completion
Jun 15, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3%

Primary Outcome Measure

The primary endpoint of this study is the number patients achieving F-VASI 50. [ Time Frame: Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Derm TexasDallasTexas75235
Amanda Study Coordinator
[email protected]
214-845-6426
Kelly Warren, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dallas, TX

By research site
Derm Texas· Dallas, TX

Related Studies